arrow
S

Shinji Itoh

kyushu university
H指数:46
被引数:9,521

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Claudin-18 Expression and Postoperative Prognosis in Intrahepatic Cholangiocarcinoma: Relationship with Histological Duct Type

Claudin-18表达与肝内胆管癌术后预后的关系:与组织学胆管分型的关联

2026-11-160
PRE
Prognostic Impact of the C‐Reactive Protein–Albumin–Lymphocyte ( CALLY ) Index in Patients With Hepatocellular Carcinoma Undergoing Living Donor Liver Transplantation

C‐反应蛋白–白蛋白–淋巴细胞(<scp>CALLY</scp>)指数对接受活体肝移植的肝细胞癌患者的预后影响

2026-10-120
OA
Nuclear Pan-Lysine Lactylation Immunoreactivity Is Associated With Poor Prognosis in Intrahepatic Cholangiocarcinoma

核泛赖氨酸乳酰化免疫反应性与肝内胆管癌的不良预后相关

2026-09-080
PRE
Comparison of Interferon-Based and Interferon-Free Treatments on the Prognosis of Hepatocellular Carcinoma After Hepatitis C Virus-Sustained Virological Response: A Multicenter Study

比较基于干扰素和干扰素free治疗对丙型肝炎病毒持续病毒学应答后肝细胞癌预后的影响:一项多中心研究

2026-06-110
OAAI
Regional Disparities in Case Volumes and Surgeon Distribution in Gastroenterological Surgery

胃肠外科中病例量和外科医师分布的区域差异

2026-06-090
OAAI
Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study

全国性前瞻性研究中的真实世界证据:不可切除肝细胞癌系统性治疗的有效性/安全性分析——PRISM研究的前1000例患者

2026-05-010
PRE
Can machine learning predict vessels that encapsulates tumor cluster ptterns and histological differentiation in solitary small (< 5 cm) hepatocellular carcinoma?

机器学习能否预测包裹肿瘤簇模式和病理分化的孤立性小 (< 5 cm) 肝细胞癌?

2026-05-010
PRE
ASO Visual Abstract: Cyclic GMP–AMP Synthase Expression in Hepatocellular Carcinoma: A Double-Edged Biomarker for Prognosis and Immunotherapy Response

ASO视觉摘要:环鸟苷酸-腺苷单磷酸合成酶在肝细胞癌中的表达:预后和免疫治疗反应的双刃剑生物标志物

2026-02-190
PRE
Consensus Meeting of Anatomy on the Border, Appropriate Use and Precautions for ICG in Liver, Lung, and Renal Surgery

解剖学边界、肝、肺和肾手术中吲哚菁绿(ICG)的合理应用及注意事项专家共识会议

2025-11-250
OAAI
Details and Updates From the Consensus Meeting on Anatomical Borders for ICG Usage in Urological Laparoscopic and Robotic Kidney Surgery

解剖边界在泌尿外科腹腔镜及机器人肾脏手术中ICG使用的共识会议详情与更新

2025-11-130
OAAI
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT

阿替利珠单抗联合贝伐珠单抗用于不适合TACE治疗的超出Up-To-7标准的中间阶段肝癌:REPLACEMENT研究的最终分析

2025-11-030
OAAI